Alys Is An Asset Play Wanting Big Pharma Attention

  
Generate a summary of this article
Listen to this article
Beta

Leaders of a new dermatology-focused biotech, which has launched with 14 development programs in its pipeline, explain the rationale behind the company creation and the ideal exit scenario.  

Business Growth Concept_1089895325_1200.jpg

Alys Pharmaceuticals launched in February 2024 with $100m seed financing from health care-focused investment firm Medicxi and the backing of world-leading experts in the field. Francesco De Rubertis, chair of Alys and a partner at Medicxi, and chief operating officer Thibaud Portal explained to In Vivo the rationale behind merging six companies to create an ambitious immuno-dermatology group.

Alys combines the assets of three US-based start-ups (Aldena Therapeutics, Klirna Biotech and Nira Biosciences) and three headquartered in the...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

SpotifyApple PodcastsWebsite

More from C-Suite Speaks

Vigya test infogram

add a desc test

Bristol Myers Squibb ASPIREs For Access In LMICs

BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.

Crossject Tackles Needle Phobia In Emergency Settings

 
• By Anabel Costa-Ferreira

Patrick Alexandre, Crossject CEO, discusses crucial developments happening for Zeneo, a needle-free injector, functioning intramuscularly to administer medication in a tenth of a second

More from Leadership

In Vivo’s 2026 Rising Leaders

 
• By Saba Afreen

The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.

How To Decarbonize Pharma R&D

As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.